Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Op-Eds
  • Video
  • Podcasts
  • Investor Watch
  • Write for us
  • News for You
  • Op-Eds
  • Video
  • Podcasts
  • Covid-19
  • Investor Watch

Topic: Challenging Results

Ivermectin Fails to Statistically Beat Placebo in Columbian Study & Mass Media Finally Takes Notice—An Interesting Observation

Recently, the results of a new ivermectin study out of Columbia were reported in the medical journal JAMA. Led by Eduardo […]

Ivermectin Fails to Statistically Beat Placebo in Columbian Study & Mass Media Finally Takes Notice—An Interesting Observation
22 hours ago
Share

MS Patients Rarely Perfectly Adhere to Medication Regimen Concludes Massachusetts General Hospital-led Virtual Clinical Trial

A recent study sponsored by Massachusetts General Hospital in collaboration with the National Multiple Sclerosis Society and Pillsy Inc. was […]

MS Patients Rarely Perfectly Adhere to Medication Regimen Concludes Massachusetts General Hospital-led Virtual Clinical Trial
6 days ago
Share

AstraZeneca’s Phase 3 KESTREL Trial of Imfinzi Fails to Meet the Primary Endpoint in Patients with Head and Neck Cancer

AstraZeneca reported that its Phase 3 KESTREL trial of Imfinzi (durvalumab) failed to meet the primary endpoint of improving overall […]

AstraZeneca’s Phase 3 KESTREL Trial of Imfinzi Fails to Meet the Primary Endpoint in Patients with Head and Neck Cancer
3 weeks ago
Share

Galapagos and Gilead Discontinue Phase 3 ISABELA Program of Ziritaxestat in IPF

Galapagos and Gilead have halted the phase 3 ISABELA program, consisting of two studies evaluating ziritaxestat in patients with idiopathic […]

Galapagos and Gilead Discontinue Phase 3 ISABELA Program of Ziritaxestat in IPF
3 weeks ago
Share

South African Gov. Halts Temporarily Oxford Vaccine Trial In South Africa Due to Low Efficacy Against the South African Variant

The South African government, via South Africa Health Minister Dr. Zweli Mkhize, declared a temporary hold on the AstraZeneca (Oxford) […]

South African Gov. Halts Temporarily Oxford Vaccine Trial In South Africa Due to Low Efficacy Against the South African Variant
4 weeks ago
Share

Amgen Pauses or Discontinues Several Therapeutics in Oncology Pipeline

Amgen released its financial results for the fourth quarter and full year 2020. Among the key results, Amgen disclosed that […]

Amgen Pauses or Discontinues Several Therapeutics in Oncology Pipeline
4 weeks ago
Share

Concert Pharma’s Adjunctive Schizophrenia Treatment, CTP-692, Fails to Meet Phase 2 Endpoints

Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did […]

Concert Pharma’s Adjunctive Schizophrenia Treatment, CTP-692, Fails to Meet Phase 2 Endpoints
4 weeks ago
Share

Biogen Discontinues Development of Parkinson’s Drug Following Disappointing Phase 2 Data

Biogen announced in its annual results and earnings presentation that its Phase II SPARK study of cinpanemab (BIIB054), under development for Parkinson’s […]

Biogen Discontinues Development of Parkinson’s Drug Following Disappointing Phase 2 Data
4 weeks ago
Share

Favipiravir Fails to Help Moderate to Severe Hospitalized COVID-19 Cases However May Lead to Modest Reduction in Duration of Hospitalization

A Kuwait-based clinical trial sponsored by Indian generic drug producer Dr. Reddy’s Laboratory was recently terminated as the resulting data […]

Favipiravir Fails to Help Moderate to Severe Hospitalized COVID-19 Cases However May Lead to Modest Reduction in Duration of Hospitalization
1 month ago
Share

BioHaven’s Troriluzole Fails Co-Primary Endpoints in Phase 2 Trial for Mild-to-Moderate Alzheimer’s Disease

BioHaven Pharmaceuticals announced the outcome from a focused analysis of the topline co-primary and key secondary data from its Phase […]

BioHaven’s Troriluzole Fails Co-Primary Endpoints in Phase 2 Trial for Mild-to-Moderate Alzheimer's Disease
1 month ago
Share

Posts navigation

Older posts

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.